Abstract:Context and objectives: Synthetic cannabinoids are illegal drugs of abuse known to cause adverse neurologic and sympathomimetic effects. They are an emerging health risk: 11% of high school seniors reported smoking them during the previous 12 months. We describe the epidemiology of a toxicologic syndrome of acute kidney injury associated with synthetic cannabinoids, review the toxicologic and public health investigation of the cluster, and describe clinical implications of the cluster investigation. Materials and methods: Case series of nine patients affected by the toxicologic syndrome in Oregon and southwestern Washington during May-October 2012. Cases were defined as acute kidney injury (creatinine > 1.3 mg/dL) among persons aged 13-40 years without known renal disease who reported smoking synthetic cannabinoids. Toxicology laboratories used liquid chromatography and time-of-flight mass spectrometry to test clinical and product specimens for synthetic cannabinoids, their metabolites, and known nephrotoxins. Public health alerts informed clinicians, law enforcement, and the community about the cluster and the need to be alert for toxidromes associated with emerging drugs of abuse. Results: Patients were males aged 15-27 years (median, 18 years), with intense nausea and flank or abdominal pain, and included two sets of siblings. Peak creatinine levels were 2.6-17.7 mg/dL (median, 6.6 mg/dL). All patients were hospitalized; one required dialysis; none died. No alternate causes of acute kidney injury or nephrotoxins were identified. Patients reported easily purchasing synthetic cannabinoids at convenience, tobacco, and adult bookstores. One clinical and 2 product samples contained evidence of a novel synthetic cannabinoid, XLR-11 ([1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone). Discussion and conclusion: Whether caused by direct toxicity, genetic predisposition, or an as-yet unidentified nephrotoxin, this association between synthetic cannabinoid exposure and acute kidney injury reinforces the need for vigilance to detect new toxicologic syndromes associated with emerging drugs of abuse. Liquid chromatography and time-of-flight mass spectrometry are useful tools in determining the active ingredients in these evolving products and evaluating them for toxic contaminants.

Convulsions Associated with the Use of a Synthetic Cannabinoid Product

Spice/K2 drugs--more than innocent substitutes for marijuana

Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study

A New Differential Diagnosis: Synthetic Cannabinoids-Associated Acute Renal Failure

Toxicological findings of synthetic cannabinoids in recreational users

Oneiroid catatonia due to the usage of spice: The case study

Acute kidney injury associated with smoking synthetic cannabinoid

Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health

Synthetic cannabinoid identification in cases associated with blue lotus and valerian root vaping products

Neurological Complications of Cannabinoids

“Spice”-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014–2020)

A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)

Acute effects of synthetic cannabinoids on ventricular repolarization

Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis

A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids

CB Cannabinoid Receptor Agonists Induce Acute Respiratory Depression in Awake Mice

Cannabis induced cardiac arrhythmias: a case series

The synthetic cannabinoids menace: a review of health risks and toxicity

Acquired Thrombotic Thrombocytopenic Purpura (TTP) Presenting With Synthetic Cannabinoid Use

CB 1 Cannabinoid Receptor Agonists Induce Acute Respiratory Depression in Awake Mice

Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling